Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IR at CNB. has not replied to emails/messages in months.
My new hashtag is #TiredOfPissPoorPress
Let us know if you hear anything from VDRM IR.
Thank you, Jim
What price do you expect it to go to? I bought in between .018 and .04 back in 2017. Do you expect it to meet or beat those levels?
It has dropped so low, I am trying to figure out what success is expected to look like.
Thank you, Jim
It is a great product and I have talked to the owner one of the dispensary chains that sell the pills and they love them as they sell great at their locations and their customers love them, but you'd never know that from the piss poor press CNBX does.
CNBX has said more than once that it is made up of scientists, not PR people, but you'd think those scientists could place a freaking want ad for a press person.
For sixty thousand a year, I would do it, and that would be a steal for what they are losing.
#TiredOfPissPoorPress
From July 3rd. Will we hear some real noise from this? Get some real PRs? Or just another thud of a PR? #TiredOfPissPoorPress
"The official results are now being evaluated by the Hospital and we expect them to be published in the next few months according to Professor Gil Bar-Sela, who ran the study and is Deputy Director of the Division of Oncology at Rambam Health Care Campus, Head of the Palliative and Supportive Oncology Unit, and Head of the service for Melanoma and Sarcoma patients.
The study is registered with the US NIH under "Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients", Identifier NCT02359123, and may be found at" https://clinicaltrials.gov/ct2/show/NCT02359123
https://finance.yahoo.com/news/cannabics-pharmaceuticals-announces-conclusion-clinical-123000354.html
I have never seen OWC$ to have had products in the market and successful studies like CNBX.
I bought some OWC$ based on advice when all of the stocks were rising. I had just liquidated out of LG$ due to they had split their stock after going from $ 15 to hitting $ 41 and I was not happy with where things were going and had a nice nest egg to invest.
My mistake, as none of the stocks had product/research like CNBX. I wish I had just put it all in CNBX.
Thanks for the clarification! Jim
Sister Stock? Please elaborate. Thanks, Jim
Why didn't CNBX do anything about this? I did the legwork for them to get OTC to put in writing that they never announced a review of CNBX, yet Brochstein's article compared CNBX to CANN, a company that had been caught doing illegal activities, and he lumped them all together in one article, smearing CNBX and within days the stock tumbled from $ 7.60 and has never made it back.
OTC asked that CNBX put out a press release, but OTC themselves and no one else did any official scrutiny. Brochstein was just allowed to skewer CNBX because they were not in his portfolio and made him look bad as an advisor when he didn't include them in companies to watch.
We were climbing from September on until this article that blatantly lied and included a company CNBX had nothing to do with that had gotten caught doing illegal things. Real nice of him to release an article comparing them as we were climbing.
Why was nothing done about this?
Sounds similar to a landlord that releases a fake rumor about a competitor's building having roaches so his building gets more tenants.
They have been participating in things that could have produced positive press releases but they continue to post what they have coming up in the near future and then never following up with press releases.
I have asked that they also start to include photos of participating to help give some "art" to the articles. Show us at that you went to this or that. Do an actual press release.
The website is down today, they have not been responding to emails most of the year, and they seem happy to let it just bleed off. Yet they are supposedly paying the fees and costs with attending conventions, etc.
Either they are in talks with someone and do not want/cannot say anything or they are allowing a company that was at $ 7.60 less than 18 months ago to whither on the vine.
In the meantime, other MMJ stocks with lesser products are at a pps of $ 135 today. This stock should be at at least $ 30 to $ 40 based on what they have and the success of trials.
What are your thoughts? I know the entire sector is down and summer is usually a quiet time, but CNBX has participated in a couple conventions/meet & greets as of late and there has been basically no press.
I have not been getting email replies like I did when Itamar was CEO. When I did bomb them with emails trying to get a reply, they sent me this:
"info cannabics <info@cannabics.com> May 24
to me
Hello Jim,
First of all allow me to apologize for the delay in our response.
I wanted to assure you that we are indeed here.
Thank you,
Cannabics Pharmaceuticals"
No answers to questions. No correspondence. Just assurance they are there. I have sent other emails since with no reply.
I have been doing research on CNBX since 2014 and invested since early 2015 and this is the worst they have ever been about contact.
Has anyone else tried to contact them?
Thank you, Jim
CNBX Website Is Down. Main & Investors page. I sent them a message as well as asking that they put photos in their PR's. Here is what I sent:
Your website is down. I have checked it from a couple different systems and it says "pageok" on the main page, investors page, etc.
Also, could you please do an article with photos of CNBX attending the National Cannabis Industry Association's Cannabis Business Summit and Expo Held at San Jose Convention Center, July 25-27, 2018?
CNBX has attended a couple conventions but we have never had any photos to go along with the articles.
I think some "art" accompanying the articles instead of the sterile PR's we normally get would go a long way in helping show CNBX is participating in events.
Thank you!
I submitted the request below via CNBX's website as well as their email, info@cannabics.com. If anyone wants to send a similar message or copy and paste mine, that would be great. I think we'd get a lot more out of these conventions if the articles included photos of CNBX attending. I know people may say that is not possible as some conventions do not allow photos, but even a photo in front of a convention banner or of CNBX execs chatting with people would be better than nothing.
"Could you please do an article with photos of CNBX attending the National Cannabis Industry Association's Cannabis Business Summit and Expo Held at San Jose Convention Center, July 25-27, 2018?
CNBX has attended a couple conventions but we have never had any photos to go along with the articles.
I think some "art" accompanying the articles instead of the sterile PR's we normally get would go a long way in helping show CNBX is participating in events.
Thank you! "
Hi Chuck,
Per your "No info at web site. Please update price (pps) update if posible" reply to my question about Investor Relations contact: Are you saying you have contacted Investor Relations and received no "info" or is this something else?
Itamar used to be great with replies and I have not found that to be the same since he left so my post was a request for feedback regarding other people's contact as well as if they were receiving news about an expected up trend.
Please clarify. Thank you, Jim
Has anyone talked to Investor Relations and has anyone seen anything that would suggest this is going to move up drastically (to around $ 20 pps)?
I don't normally talk dollar amounts and instead present compiled news, but I want feedback on any recent Investor Relations talks and any discussion regarding a quick rise.
Thank you for your time if you have any info regarding above.
Jim
YES!! We need this kind of news!!
The clearest, most concise information VDRM has ever released!!!
http://viadermalicensing.com/img/ViaDermaNote.pdf
This is fantastic news. Nice to see CNBX popping up in numerous articles again.
Hopefully, after the July 1st through 4th meetings, they do some follow-up press.
With the recent news of the US Government accepting medical MJ for epilepsy (finally!!!), we are in a nice news cycle right now.
Take care, Jim
Who in the Hell is GWPH paying off to keep getting such preferential treatment with lesser products?
Their first big hitter was a 4 hour spray compared to CNBX's 12 hour long release pill. Which is more like traditional medicine? Easier to control? Less apt to spill in a purse, etc?
CNBX has had the market on this longer and with more studies.
And CNBX is under a dollar while GWPH is over $ 140??? When is CNBX going to hit at least $ 20 with the tested products they have in market? $ 100????
I call favoritism with a lesser product.
Jim
Some would say that MJ and MMJ always take a break in the summer, and then pick up around election time.
I am hoping that CNBX has a different cycle this summer in light of the recent activity they have had in 2018 (review my previous posts if need a list of everything positive they had done differently this year compared to other years).
It is simply not making sense that they have done so much and are keeping so quiet about it. I do not believe they even released follow up PR's after presenting at recent conventions, etc.
For a long time I would cull the web, find info and post it for them, but I think it is time they put some of the recent news together and try to capitalize on it.
They have said they are doctors and that they are not interested in doing PR, but I would hope some of the recent investors (thirteen million dollars from 2 investors alone) would start to ask CNBX to promote so they see a return on their investment.
There has been a lot of talk about what CNBX may be doing, but I think it is time people start asking IR to put out some press. I have reached out to them, and since the previous CEO left, they are much less apt to respond. Please feel free to use their contact page and ask for info.
I'd love to see some fresh news that has both a beginning and an end to any given story. Please post here if you contact them.
Thank you, Jim
Fantastic seeing common sense in action! “We have seen in the Senate tonight a historic vote that ends 90 years of prohibition of cannabis in this country, 90 years of needless criminalization, 90 years of a just-say-no approach to drugs that hasn’t worked,” said independent Sen. Tony Dean, who sponsored the bill in the upper house.
http://nationalpost.com/cannabis/cannabis-news/cannabis-legalization/a-historic-vote-senate-passes-marijuana-bill-clearing-way-for-legalization
Well, Mavi & Retired, I will land in the middle and say that for a company that has so much going for it and so much recent news, we sure are not hearing much about it.
Has anyone else contacted their investor relations? I did and they assured me they are there. Not quite what I was going for, but after not receiving responses, I did kind of carpet bomb their CONTACT US page. I guess the assurance they provided me was kind of on par with the assurances and press they are providing every other day.
Not asking for constant reports, but again, with as much as they have going on, they need to promote it.
Have a great weekend. Jim
Indeed, I was very happy to log on and see green!!
This company is getting better press globally than it ever has, yet we are not seeing a bump in pps.
Hiring new doctors, hiring staff, a 3 million dollar investor, a 10 million dollar investor that they were supposed to start taking advantage of this week (6-4 was the anticipated sale date), presenting at various conventions and conferences, a report that brought great news, and Canada getting ready to go all in with MJ.
Yet it just seems that they cannot put out the right kind of press or garner the right kind of attention for take-off.
I don't get it. I researched CNBX through 2014, bought in in early 2015, less than a year ago we of course spiked to over a $ 7 pps, I would think they would either have a buyer (which has been rumored) or would have more success than we are seeing.
Don't get me wrong, a stock that was 3 cents a share in June 2016 being at a dollar in June 2018 is still a great return, but I expect so much more from the good news.
If anyone has news, articles, etc, please share. I have been busy and not doing as much CNBX homework so would love to see anything you come across. Please include links with any news posted.
Take care, Jim
A great read indeed Scuba2! I tried to copy it but trying to copy into Word from an Israeli website was a nightmare so, as Scuba2 recommended, I recommend translating it and taking a quick read on what Israel has to say about CNBX.
https://www.globes.co.il/news/article.aspx?did=1001239724
Thanks, Scuba2! Jim
What follows is a dissemination of news of the day regarding CNBX:
Joined "The Wolf of Penny Stocks" today, as it seems to combine a lot of the day's stories but promises no spam.
Also joined because they had an alert (as did others without same anti-spam promise) that all said the same statement: "CNBX IS NOW ON WATCH BY WALL STREET´S HOTTEST NEWSLETTER!".
When I see the exact same tagline on various sites, either they are all written by the same person or they picked it up something somewhere. Hopefully, it is a sign CNBX is moving up in interest since it was their banner story.
In industry news, they had:
July 1 Will Be HUGE For The Marijuana Industry
On July 1 California's recreational marijuana laws go into effect. That will be HUGE for the marijuana industry... And for anyone who's invested in it.
Again, just sharing what the site had as headlines, but hopefully it is positive news for CNBX.
https://thewolfofpennystocks.com/
CNBX is set to sell 318,547 shares today as part of their deal with YAII PN Ltd (6-4-18). Will be interesting if such a jump in volume draws any attention.
Very glad to see they are exercising this option set in motion back in April.
Will be interesting to see how, instead of flooding the market with shares like other companies do, actual sales and a boost in volume effects the stock.
Here is the link to the prospectus:
https://ih.advfn.com/p.php?pid=nmona&article=77576835
Join Cannabics Pharmaceuticals at LCBC Cannabis Professional Conference Held at MTCC, Toronto, Canada, May 25-27, 2018
May 24, 2018 09:00:00 (ET)
TEL AVIV, Israel and BETHESDA, Maryland, May 24, 2018 /PRNewswire/ --
Cannabics Pharmaceuticals (OTCQB: CNBX), a US, public bio-pharma company dedicated to developing precision medicine solutions for personalized anti-cancer diagnostics and palliative cannabis-based treatments, announced today that its management members are to attend The Lift & Co. Expo (LCBC), Canada's biggest professional cannabis business conference, to be held this week at MTCC, Toronto, Canada.
Cannabics Pharmaceutical's breakthrough technology is based on non-intrusive diagnostic testing for cancer patients, to be employed for selecting the most appropriate and optimal Cannabinoid-based therapies and medications applied to specific patients based on their molecular/cellular screening analysis results.
Join them in Toronto this week!
The company's CEO, Mr. Eyal Barad, will accept one-on-one meetings.
To schedule meetings and any other inquiry, please contact us at: ir@cannabics.com
Link to today's article: https://www.prnewswire.com/news-releases/join-cannabics-pharmaceuticals-at-lcbc-cannabis-professional-conference-held-at-mtcc-toronto-canada-may-25-27-2018-683575521.html
About Cannabics Pharmaceuticals Inc.
Cannabics Pharmaceuticals Inc. (CNBX) is a US bio-pharma company dedicated to developing precision medicine personalized anti-cancer diagnostics and cannabis based treatments. It is based on Israeli R&D licensed by the Israeli Ministry of Health for scientific and clinical research. Cannabics novel technology pioneers the assimilation of precision medicine into Cannabinoid-based therapies for cancer patients, utilizing original, patented screening technologies, data management and artificial intelligence (AI).
Disclaimer:
I found a link to his departure but I am surprised I hadn't seen something about this before. Figured it would have been a topic here and at Etrade, etc.
Here is the link regarding his departure.
http://www.4-traders.com/CANNABICS-PHARMACEUTICALS-16746420/news/CANNABICS-PHARMACEUTICALS-INC-Change-in-Directors-or-Principal-Officers-Financial-Statements-and-25898710/
Thank you, Jim
Cannabics Pharmaceuticals Hires Two New Scientists to Further Develop Cannabinoid Diagnostic Tests and Treatments for Cancer
PR Newswire PR NewswireMay 22, 2018
Dr. Haleli Sharir and Dr. Nir Kfir bring expertise in cannabinoid research and high-content screening assessments.
TEL AVIV, Israel and BETHESDA, Maryland, May 22, 2018 /PRNewswire/
-- Cannabics Pharmaceuticals Inc. (CNBX), leader in cannabinoid diagnostic tests for personalized cancer treatment, announced today the appointment of Haleli Sharir, Ph.D. as principal scientist and Nir Kfir, Ph.D. as senior scientist. The two new team members will support Cannabics' data-discovery process with the goal of identifying new cannabinoid diagnostic tests and treatments for cancer.
Dr. Sharir is widely recognized for her role in identifying a potentially new cannabinoid receptor, GPR55. She was a member of a research group responsible for discovering that human GPR55 is activated by several types of cannabinoids. Dr. Sharir has published nine peer-reviewed research papers on the topic. The research was funded by the National Institute of Health (NIH/NIDA), and results are available through the National Center for Biotechnology Information (NCBI).
Dr. Sharir is also proficient in the development, optimization and implementation of high-throughput screening (HTS) and high-content screening (HCS) assessments – approaches to cell biology that are used for large-scale applications.
Dr. Kfir has a background in molecular genetics and specializes in RNA processing and chromatin organization. His previous work has focused on HTS and on researching new chemotherapy treatments that restore a cancer cell's ability to undergo "programmed cell death".
"Dr. Sharir and Dr. Kfir's experience will effectively guide Cannabics' data discovery process and will streamline our compound screenings," said Cannabics Pharmaceuticals Co-Founder and CEO Eyal Barad. "The combined expertise of these leading scientists will help us develop and implement HCS analysis to address the effects of cannabinoids on cancer growth."
See Article Here: https://finance.yahoo.com/news/cannabics-pharmaceuticals-hires-two-scientists-143200819.html
About Cannabics Pharmaceuticals
Cannabics Pharmaceuticals Inc. (CNBX) is a United States-based public company that is developing cannabinoid diagnostic tests for the personalized treatment of cancer. Cannabics is developing a blood test that allows practitioners to precisely tailor medical cannabinoid-based therapies to an individual patient's profile and cancer. Cannabics' approach can also be used to develop cannabinoid-based therapies as preventive or primary cancer treatments – not just palliative, the way it's being used now. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move medical cannabinoids into the mainstream of cancer therapies.
The company's R&D is based in Israel, where it is licensed to conduct scientific and clinical research on harnessing the therapeutic properties of cannabinoid formulations. For more information, please visit www.cannabics.com.
Disclaimer:
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on April 6th, 2018. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
I emailed Itamar regarding the Twitter and Contact issues.
His last response mentioned that the site had been having issues and that they are planning to hire more staff to handle PR/IR.
I will advise if I hear or see anything else.
Thank you, Jim
That surprises me with all of the news that they have had this year (New Hires, Cannatech, etc).
Thanks for the info Matt! Jim
Has anyone else emailed CNBX through their "Contact Us" form and gotten the odd "Send Message - OK" box that pops up after clicking send?
That wording feels more like a question than a statement, but when the box appears, your text and contact information boxes have cleared.
I typically get a response within a day when I send emails to CNBX, but as of late I am not getting replies and I question if that box is possibly an issue on my end or theirs.
Odd wording for a confirmation and I do not remember getting that box in the past.
Please advise if anyone else has emailed and if you have had success.
Thank you, Jim
WOW!!! Over 1 million, ninety-seven thousand shares at .0085 on the Ask! Haven't seen an Ask like that in awhile!!!!
VIADERMA INC COM
VDRM:NSDQ
Last Price Today's Change Volume
0.00848 +0.00068(+8.72%) 811,684
Bid (Size) Ask (Size) Prev. Close
0.008(161200) 0.0085(1097668) 0.0078
So come Tuesday, YAII can buy ten million dollars worth of shares at a 2 % discount.
It will be interesting, since the price is currently around $ 1, to see how quickly they exercise their right to buy so as to maximize the number of shares they can buy.
They have 36 months to spend the 10 million dollars, so to take advantage of the deal, they have to average around 3 million dollars a month over the 3 years.
3 million extra shares a month! Not too shabby of a deal for us shareholders!!!!
This is some of the best news I have seen come out of CNBX.
Here is the excerpt and a link to the 8K that stated this is below:
On April 30 th , 2018, the Company entered into a Standby Equity Distribution Agreement (the “Agreement”) with YAII PN, Ltd., ("YAII PN Ltd.”). The Standby Equity Distribution Agreement (SEDA) with YAII PN enables the selling of up to $10,000,000 of our common stock at the Company’s request any time during the 36 months following the date of the agreement entered on May 8 th , 2018. The shares would be purchased at 98% of the market price and would be subject to certain limitations, including that YAII PN could not purchase any shares that would result in it owning more than 4.99% of our common stock.
Pursuant to the Purchase Agreement, we are required to register all shares which YAII PN Ltd. may acquire. The Company shall file with the Securities and Exchange Commission a prospectus supplement to the Company's prospectus, dated April 21, 2017, filed as part of the Company's effective shelf registration statement on Form S-3, File No. 333-216845, registering all of the shares of Common Stock that are to be offered and sold to YAII PN Ltd. pursuant to this Agreement.
Pursuant to the Agreement, we shall use the net proceeds from any sale of the shares for working capital purposes and capital expenditures. There are no other restrictions on future financing transactions. The Purchase Agreement does not contain any right of first refusal, participation rights, penalties or liquidated damages. We did not pay any additional amounts to reimburse or otherwise compensate YAII PN Ltd. in connection with the transaction.
YAII PN Ltd. has agreed that neither it nor any of its affiliates shall engage in any short-selling or hedging of our Common Stock during any time prior to the public disclosure of the Agreement.
https://ih.advfn.com/p.php?pid=nmona&article=77322977
The big thing that jumped out at me that is a huge positive compared to other companies that are funding their work via dilution:
"...the Securities and Exchange Commission registered all common stock shares to be offered and sold by YAII PN, Ltd., which enables substantially less dilution for existing shareholders when compared to convertible transactions or direct loan agreements".
So instead of dumping fresh shares on the market to fund itself, which greatly diminishes stock price, this set up allows for less dilution. Very nice!!!
https://www.prnewswire.com/news-releases/cannabics-pharmaceuticals-announces-collaboration-with-life-source-partners-ceo-muriel-zohar-to-optimize-technology-applications-and-evaluate-new-opportunities-681496381.html
Thanks for sharing Matt! Jim
I think it will fluctuate a few cents here and a few cents there, but CNBX has taken actions in the last year that a faux/failing company would not spend the money to take. (Hiring of high-level staff, etc).
I agree that we have things coming up as early as this month that have created a situation where we are basically at the current bottom and will be going up a nickel here, a dime there, a quarter another day, from here until something major happens.
We seem to finally have the federal government, the news cycle (NBC, etc), and high profile converts like John Boehner all going our way.
With that, you nailed it: Test results and treating patients via biopsy and/or pill and we are off and running.
April 19th, 2018 NBC Nightly News with Lester Holt - https://www.nbcnews.com/nightly-news/video/fda-panel-recommends-marijuana-product-to-treat-epilepsy-1215027267691
April 20th, 2018 NBC Nightly News with Lester Holt - https://www.nbcnews.com/nightly-news/video/legalization-of-recreational-marijuana-gaining-support-on-4-20-1215925827803
Take care, Jim
Unlike a lot of boards, CNBX followers, for the most part, only post when there is news released, etc.
Not a lot of guessing or chatter. Just the facts, so to speak.
Stay tuned. May will hopefully be interesting.
Take care, Jim
Following article leads the way. We are there!
https://www.investors.com/news/technology/gw-pharmaceuticals-epidiolex-fda-committee/
GW has led the way all along, and CNBX has followed with an even better product and biopsy options, taking longer to make a better mousetrap so to speak.
What was 3 cents a share in June 2016 will be dollars in 2018.
GLTA!!! Jim
10:34 AM and no volume... literally 0 trades even though there are thousands of Bids and Asks... ????
Below is pasted from Etrade
VIADERMA INC COM
VDRM:NSDQ
Last Price Today's Change Volume
0.0085 0.00(0.%) 0
Bid (Size) Ask (Size) Prev. Close
0.0078(214230) 0.0084(50000) 0.0085
Real Time Quote Last Trade 9:55 AM ET 4/12/18